All In Biotech

Drug Trial Radar · NCT07226856

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Dec 12, 2025

Primary completion

Feb 28, 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the safety, side effects and best dose of BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel and how well it works in treating patients with pancreatic adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that has come back after a period of improvement (recurrent). BMS-986340 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel may be safe, tolerable, and/or effective in treating patients with metastatic or recurrent pancreatic adenocarcinoma.

Conditions

  • Metastatic Pancreatic Adenocarcinoma
  • Recurrent Pancreatic Adenocarcinoma
  • Stage IV Pancreatic Cancer AJCC v8

Interventions

  • Biopsy ProcedureProcedure

    Undergo tissue biopsy

  • Biospecimen CollectionProcedure

    Undergo urine and blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • GemcitabineDrug

    Given IV

  • ImzokitugBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo brain MRI

  • Nab-paclitaxelDrug

    Given IV

  • NivolumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of significant adverse events (AEs) (Safety Run-in)Time frame: During cycle 1 (cycle length = 28 days)
  2. Objective response rate (Phase II)Time frame: Up to 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.